Lucia Pantani

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study

Michèle Cavo, Paola Tacchetti, Francesca Patriarca et al. · The Lancet · 2010 · 818 citations

Hematological Malignancy, Transplantation, Marrow Transplantation +10

Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation

Elena Zamagni, Francesca Patriarca, Cristina Nanni et al. · Blood · 2011 · 518 citations · Full text

Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

Michèle Cavo, Francesca Gay, Meral Beksaç et al. · The Lancet Haematology · 2020 · 377 citations · Full text

Hematological Malignancy, Transplantation, Marrow Transplantation +9

Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

Michèle Cavo, Lucia Pantani, Maria Teresa Petrucci et al. · Blood · 2012 · 309 citations · Full text

PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma

Elena Zamagni, Cristina Nanni, Katia Mancuso et al. · Clinical Cancer Research · 2015 · 169 citations